Canada - engleză - Health Canada

abbvie corporation - adalimumab - solution - 40mg - adalimumab 40mg - disease-modifying antirheumatic agents

Canada - engleză - Health Canada

abbvie corporation - adalimumab - solution - 80mg - adalimumab 80mg - disease-modifying antirheumatic agents

Canada - engleză - Health Canada

abbvie corporation - adalimumab - solution - 80mg - adalimumab 80mg - disease-modifying antirheumatic agents

Canada - engleză - Health Canada

abbvie corporation - adalimumab - solution - 10mg - adalimumab 10mg - disease-modifying antirheumatic agents

Canada - engleză - Health Canada

abbvie corporation - adalimumab - solution - 20mg - adalimumab 20mg - disease-modifying antirheumatic agents

Singapore - engleză - HSA (Health Sciences Authority)

ehc supply - dental - nobelclinician is a software interface for the transfer and visualization of imaging information from equipment such as a ct scanner for the purposes of diagnosis and treatment planning in the dental and cranio-maxillofacial regions. the nobelclinician software can be used to design a surgical template for the purposes of aiding placement of dental implants.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

advanced bionics australia pty ltd -

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

trupharma, llc - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

remedyrepack inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adeq

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.